Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Intangibles: 2017-2023

Historic Intangibles for Aclaris Therapeutics (ACRS) over the last 6 years, with Dec 2023 value amounting to $751,000.

  • Aclaris Therapeutics' Intangibles fell 89.82% to $751,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $751,000, marking a year-over-year decrease of 89.82%. This contributed to the annual value of $751,000 for FY2023, which is 89.82% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Intangibles of $751,000 as of Q4 2023, which was down 89.82% from $7.4 million recorded in Q3 2023.
  • In the past 5 years, Aclaris Therapeutics' Intangibles ranged from a high of $73.8 million in Q1 2019 and a low of $751,000 during Q4 2023.
  • Moreover, its 3-year median value for Intangibles was $7.4 million (2023), whereas its average is $6.8 million.
  • Per our database at Business Quant, Aclaris Therapeutics' Intangibles spiked by 909.37% in 2019 and then slumped by 90.00% in 2020.
  • Quarterly analysis of 5 years shows Aclaris Therapeutics' Intangibles stood at $7.4 million in 2019, then remained steady at $7.4 million in 2020, then remained steady at $7.4 million in 2021, then remained steady at $7.4 million in 2022, then crashed by 89.82% to $751,000 in 2023.
  • Its Intangibles was $751,000 in Q4 2023, compared to $7.4 million in Q3 2023 and $7.4 million in Q2 2023.